ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2761

Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis

Berivan Bitik1, Berna Goker2, Kubilay Sahin3, Yesim Sucullu Karadag4, Ridvan Mercan5, Abdurrahman Tufan1, Mehmet Akif Ozturk1, Fikri Ak4, Yasar Karaaslan6,7 and Seminur Haznedaroglu1, 1Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, 2Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, 3Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, 4Neurology, Ankara Numune Education and Research Hospital, Ankara, Turkey, 5Gazi University School of Medicine, Ankara, Turkey, 6Rheumatology, Hitit University, Corum, Turkey, 7Ankara Numune Training and Research Hospital, Ankara, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and uveitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Behcet’s Syndrome (BS) is a systemic vasculitis which may involve multiple organ systems simultaneously. Most frequently, clinical findings in BS fit into well recognized patterns such as the association between papulopustular skin lesions and arthritis.  Neurological involvement in BS is a serious condition which could lead to significant disability. It could either be parenchymal or vascular. The pathogenesis of these two types of Neuro-Behcet’s Syndrome (NBS) are suggested to be different. The purpose of this study is to evaluate the association between the parenchymal Neuro-Behcet’s Syndrome and panuveitis.

Methods

We retrospectively reviewed the clinical records of 288 patients with BS, who met the international classification criteria for BS, diagnosed at two major rheumatology clinics from 2000 to 2014. Patient demographics, ophthalmic examinations, clinical and radiologic patterns of neurological involvement were recorded. Pearson’s Chi-square test was used for analysis.

Results

In this cohort of a total of 288 patients, 93 developed panuveitis and 38 had NBS (28 men and 10 women, median age 33 (28-54)). Of the 38 patients with neurological involvement, 28 had parenchymal and 10 had vascular disease. Venous sinus thrombosis was the only vascular involvement in NBS patients. Those with panuveitis were significantly more likely to have parenchymal neurological involvement compared to those without panuveitis (22.6% vs 3.6 %, p =0.001) (Table). 21 of the 28 parenchymal NBS patients had panuveitis either prior to or during the course of neurological involvement. Panuveitis was significantly associated with parenchymal-NBS (OR 7.83 95% CI 3.19-19.21). 

Table.  The association between panuveitis and parenchymal neurological involvement in patients with BS.

BS Patients

 

Parenchymal neurological involvement

P-value

 

Present

Absent

Panuveitis

Present

21

72

0.001

Absent

7

188

Conclusion

Among our 288 patients with BS, over one out of five cases with panuveitis had neurological involvement during their disease course. Our findings suggest a significant association between these two major organ involvements. This association might also be defined as a recognized clinical pattern, similar to the association of papulopustular skin lesions with arthritis. BS patients with panuveitis should be educated about possible signs and symptoms of neurological involvement which could progress quite rapidly and early initiation of treatment is the key for success.


Disclosure:

B. Bitik,
None;

B. Goker,
None;

K. Sahin,
None;

Y. S. Karadag,
None;

R. Mercan,
None;

A. Tufan,
None;

M. A. Ozturk,
None;

F. Ak,
None;

Y. Karaaslan,
None;

S. Haznedaroglu,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-parenchymal-neurological-involvement-in-behcets-syndrome-patients-with-panuveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology